According to the research report titled ‘Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)’, available with MarketStudyReport, global Alzheimer drugs market was worth USD 6537 million 2021 and is projected to witness substantial growth over the forecast period 2022-2027.

Increase in prevalence of chronic ailments such as obesity, diabetes, heart diseases, and high blood pressure, unhealthy lifestyle choices, coupled with rising geriatric population are the primary factors driving global Alzheimer drugs market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4597183/   

Moreover, growing number of pharmaceutical companies which are working on developing drugs that prevent Alzheimer’s disease and provide long term improvements in cognitive function are also driving industry development.

Factors such as easy access to telehealth services and surging number of online pharmacies are further promoting drug delivery and disease diagnosis in remote regions. Several Alzheimer's drugs are also undergoing late-stage clinical testing, which is expected to positively sway the market outlook in the upcoming years.

Based on drug class, worldwide Alzheimer drugs industry is segmented into cholinergic, combined drug, memantine, and others. By distribution channel, the market classification comprises online, retail, and hospital pharmacies.

On the regional front, the research literature classifies the industry into North America (United States, Canada), Europe (Germany, France, United Kingdom, Italy), Asia Pacific (Japan, India, China, Australia), and Middle East & Africa.

Speaking of the competitive landscape, firms such as NervGen Pharma, Eisai Co. Ltd., Daiichi Sankyo Co. Ltd., Novo Nordisk A/S, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Co., Pfizer Inc., Biogen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., and AbbVie Inc. prominently influence global Alzheimer drugs market trends.